A polymer, polymer micelle and preparation method and application thereof
By designing a block polymer of galactose-polyethylene glycol-poly{N-[N'-(2-aminoethyl)/(1-(3-mercaptopropyl)imino))-2-aminoethyl]aspartic acid}-pyrodeenzyme chlorophyll a, the problems of low delivery capacity of cationic polymers and difficulty in photosensitizing agents reaching target cells were solved, achieving efficient drug delivery and photodynamic therapy.
Patent Information
- Application Number
- CN202211412211.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-11-11
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2042-11-11
AI Technical Summary
In existing technologies, cationic polymers have low delivery capacity for gene drugs, making it difficult to deliver photosensitizers and drugs to target cells simultaneously. Furthermore, photosensitizers have poor solubility, making it difficult for them to reach the lesion site.
A block polymer consisting of galactose-polyethylene glycol-poly{N-[N'-(2-aminoethyl)/(1-(3-mercaptopropyl)imidazolium))-2-aminoethyl]aspartic acid}-pyrodeenzyme chlorophyll a (PPa-PAsp(DET/MPA)-PEG-Gal) is used. The polymer micelles are formed by positive and negative charge binding, which bind photosensitizer groups and drugs. The photosensitizer's photochemical internalization disrupts lysosomes, achieving intracellular drug delivery, and the micelle stability is increased by disulfide bonds.
It improves the transfection capability and drug delivery efficiency of cationic polymers, enabling the simultaneous delivery of photosensitizers and drugs to target cells, resulting in photodynamic therapy effects.
Smart Images

Figure CN115926177B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of drug carriers, and in particular to a polymer, a polymer micelle, and a preparation method and application thereof. Background Art
[0002] In recent years, immunotherapy has shown to be an important therapeutic tool for diseases such as viruses and tumors. The innate immune response is the host's first line of defense against foreign pathogens. The host can recognize pathogen-related molecular patterns through pattern recognition receptors and then initiate an antiviral immune response. The stimulator of interferon genes (STING), discovered in 2008, is an important molecule in the innate immune response. Its discovery rapidly expanded the field of immunology research and cancer immunotherapy. STING is currently a very popular target for drug development. STING agonists have been used in preclinical studies and clinical trials for a variety of tumors, showing attractive application prospects. STING inhibitors are expected to alleviate autoimmune diseases and inflammatory-related diseases.
[0003] In the inactive state, STING is anchored to the endoplasmic reticulum in the form of a butterfly-shaped dimer through several transmembrane domains. When cGAMP binds to it, the cytoplasmic domain of the STING protein will rotate 180° and untie around the intersection between the proteins, where there is a connecting loop and a connecting helix. This conformational change allows adjacent STING dimers to bind tightly to form STING oligomers. Recent studies have shown that some drug molecules can activate the body's innate immunity by activating the STING signaling pathway, achieving immunotherapy for diseases such as tumors, such as cyclic guanosine monophosphate (2',3'-cGAMP), ADU-S100, etc. Although cyclic guanosine monophosphate (2',3'-cGAMP) can activate STING immunity as an endogenous STING agonist, it has the following bottlenecks: cyclic guanosine monophosphate (2',3'-cGAMP) is a small molecule drug that has no lesion targeting function; it is easily decomposed by phosphodiesterase; cyclic guanosine monophosphate has certain toxic side effects; cyclic guanosine monophosphate has no lysosomal escape function and cannot enter the cell; after cyclic guanosine monophosphate activates STING, it will increase the expression of PD-L1 in tumor cells, causing T cells and tumor cells to "handshake", resulting in the killing effect of escaped T cells on tumor cells. Therefore, it is necessary to deliver a drug carrier for cyclic guanosine monophosphate, and at the same time, it is necessary to inhibit the immunosuppressive effect caused by the upregulation of PD-L1 caused by cyclic guanosine monophosphate activating the STING pathway.
[0004] RNA drugs are the third largest new drug after chemical drugs and biological protein drugs. They are a type of drug that can regulate biological signaling pathways at the RNA level to exert therapeutic effects. Among them, siRNA can specifically act on homologous mRNA sequences at extremely low intracellular concentrations, thereby efficiently blocking the expression of target genes or proteins. Specific siRNA can express aPD-L1 antibodies in cells to prevent T cells and tumor cells from "shaking hands" and ending the immunosuppressive effect on T cells. This requires the simultaneous administration of siRNA expressing aPD-L1 into tumor cells. However, there are some problems in the use of siRNA, such as: instability, easy to be degraded by nucleases; no lesion targeting; unable to escape lysosomes and endosomes, and will be degraded; siRNA itself has a negative charge, which is not conducive to entering cells through negatively charged cell membranes. Therefore, it is necessary to deliver siRNA into cells to express aPD-L1 to achieve synergistic effects. Although cationic polymers are now used for gene delivery, they have the characteristics of poor stability, poor targeting effect, poor transfection effect, and high toxicity with gene complexes.
[0005] Photodynamic therapy has been proven to be an effective option for treating a variety of localized and superficial cancers as a clinical method. When photoactivated drugs (photosensitizers) are activated by light, the photosensitizers absorb light energy and transition to an excited state. In the process of returning from the excited state to the ground state, the photosensitizers transfer energy to the surrounding molecular oxygen, thereby generating a large number of singlet oxygen and other free radicals with killing effects. These reactive oxygen species can kill tumor cells and destroy tumor nourishing blood vessels. In addition, photodynamic therapy causes immunogenic cell death. The cytotoxic T lymphocytes produced by this process can kill the remaining tumor cells, potential drug-resistant tumors and tumor stem cells, prolong the patient's survival and improve the patient's prognosis. It is worth noting that the oxidative free radicals produced by photosensitizers can destroy the inner membranes such as lysosomes and promote the escape of drugs, which is called photochemical internalization. Studies have shown that photochemical internalization can promote the transfection of gene drugs such as siRNA, DNA, ASO, and pDNA, but the challenge is that the gene and photosensitizer need to be delivered to the target cells at the same time. In addition, photosensitizers are planar rigid structures with poor water solubility, making it difficult to reach the lesion site. Summary of the invention
[0006] The purpose of the present invention is to solve the problems in the prior art that cationic polymers have low delivery capacity for gene drugs and are difficult to deliver photosensitizers and drugs to target cells at the same time, and to provide a polymer, polymer micelles, and a preparation method and application thereof.
[0007] In order to solve the above technical problems, the technical solution adopted by the present invention is as follows: a polymer, wherein the polymer is a galactose-polyethylene glycol-poly {N-[N'-(2-aminoethyl) / (1-(3-mercaptopropyl)amino))-2-aminoethyl]aspartate}-pyrodeoxychlorophyllin a (PPa-PAsp(DET / MPA)-PEG-Gal) block polymer; the structural formula of the polymer is shown in formula (I):
[0008]
[0009] Among them, x is 1-100; n is 1-100; m is 0-100.
[0010] The present invention provides application of the polymer in drug delivery.
[0011] The "galactose-polyethylene glycol-poly {N-[N'-(2-aminoethyl) / (1-(3-mercaptopropyl)amino))-2-aminoethyl]aspartic acid}-pyropheophorbide a (PPa-PAsp(DET / MPA)-PEG-Gal) multifunctional block polymer" of the present invention comprises: a target molecule, a photosensitizer group, a cationic polymer functional unit and a polymer functional unit with a thiol group modified on the side chain, wherein the target molecule is galactose, and the photosensitizer is pyropheophorbide a (Pyropheophorbide a,PPa); the cationic polymer functional unit is polyethylene glycol-poly{N-[N'-(2-aminoethyl) / (1-(3-mercaptopropyl)amino))-2-aminoethyl]aspartic acid} block polymer; wherein, the photosensitizer pyrochlorophyllin a has light imaging and photodynamic effects, can destroy lysosomes to help the intracellular delivery of drugs or genes; galactose can target galactose receptors or glucose receptors on the cell surface to achieve active targeting of cells; the cationic polymer functional unit can be combined with genes or negatively charged drugs to assemble into nanomedicines, and also has lysosomal escape function; disulfide bonds can cross-link the inner core of the micelles, increase the stability of the polymer micelles, and can also control the release of drugs in the cells.
[0012] The present invention provides a method for preparing a polymer, comprising the following steps:
[0013] S1, PPa-NH2 and L-aspartic acid-4-benzyl ester-N-carboxyl cyclic anhydride (BLA-NCA) undergo polymerization reaction (molar ratio, 1:10-150) to form a polymer skeleton pyropheophorbide a-polyaspartic acid (PPa-PBLA); the PPa-NH2 is an amino derivative of pyropheophorbide a (PPa);
[0014] S2, reacting the polymer backbone PPa-PBLA in S1 with maleimide-polyethylene glycol-succinimidyl acetate and 11-mercaptogalactosamine derivative (molar ratio, 1:1:1) to form a block polymer PPa-PBLA-PEG-Gal;
[0015] S3, reacting the block polymer PPa-PBLA-PEG-Gal in S2 with diethylenetriamine (molar ratio, 1:10-500) to form PPa-PAsp(DET)-PEG-Gal;
[0016] S4. The PPa-PAsp(DET)-PEG-Gal in S3 is reacted with 3,3'-dithiobis(propylimidate) dimethyl ester dihydrochloride (molar ratio, 1:10-300) to obtain a polymer PPa-PAsp(DET / MPA)-PEG-Gal.
[0017] The present invention provides a polymer micelle comprising a drug and the polymer according to claim 1.
[0018] Preferably, the drug is one or both of a gene drug and a negatively charged small molecule drug.
[0019] Preferably, the gene drug is RNA or DNA.
[0020] Preferably, the negatively charged small molecule drug is cyclic guanosine monophosphate.
[0021] Preferably, the particle size of the polymer micelle is 10-200 nm.
[0022] Preferably, the polymer and the drug are dissolved in HEPS buffer or an organic solvent respectively, mixed and self-assembled to obtain drug-loaded polymer micelles; the organic solvent is tetrahydrofuran.
[0023] The invention provides the use of the polymer micelle in preparing drugs for gene therapy, immunotherapy, phototherapy and chemotherapy.
[0024] As attached Figure 1-4 As shown, in the present invention, the derivative PPa-NH2 of the photosensitizer PPa (pyrochlorophyllin a) is used as the starting material, and the most basic polymer skeleton PPa-PBLA is formed by initiating the ring-opening polymerization of L-aspartic acid-4-benzyl ester-N-carboxyl ring anhydride, thereby introducing the photosensitizer into the cationic polymer. Then, the polyethylene glycol hydrophilic segment is introduced to form the block polymer PPa-PBLA-PEG. Then, the cationic group diethylenetriamine is introduced by aminolysis reaction. Finally, 3,3'-dithiodipropaneimidate dimethyl ester dihydrochloride introduces a thiol group in the side chain, and the stability of the loaded drug is increased by cross-linking to form a disulfide bond.
[0025] The structural analysis of the photosensitizer-containing cationic polymer PPa-PAsp(DET / MPA)-PEG-Gal in the present invention is shown in the attached Figure 4 As shown. Wherein x is the number of repeating units of 3,3'-dithiobispropanimidate dimethyl ester dihydrochloride chemically modifying the side chain of polyethylene glycol-poly {N-[N'-(2-aminoethyl)-2-aminoethyl] aspartic acid} block polymer; n is the number of repeating units of cationic diethylenetriamine units; and m is the number of repeating units of polyethylene glycol.
[0026] The beneficial effects of the present invention are:
[0027] 1) The polymer in the present invention is a cationic polymer containing a photosensitizer, which can form polymer micelles with gene drugs (siRNA, pDNA) or negatively charged small molecule drugs (cyclic guanosine monophosphate) through positive and negative charges. The polymer micelles can simultaneously deliver the photosensitizer and the drug directly to the target cells (tumor cells), solving the problem that the photosensitizer is difficult to reach the target cells due to poor solubility; and in this process, the photochemical internalization of the photosensitizer destroys the lysosomes and endosomes, thereby improving the transfection ability of the cationic polymer and further improving the drug delivery efficiency;
[0028] 2) The disulfide bonds formed by the photosensitizer-containing cationic polymers of the present invention increase the stability of the polymer micelles and can respond to the high concentration of glutathione in tumor cells, thereby slowly releasing the drugs carried in the polymer micelles;
[0029] 3) The polymer micelles formed by the cationic polymer containing the photosensitizer and the drug in the present invention have a photodynamic therapy effect on tumors. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] Figure 1 The figure is a synthetic process diagram of the amino derivative PPa-NH2 of chlorophyllin a in the present invention;
[0031] Figure 2 FIG. 1 is a diagram showing the synthesis process of the mercaptogalactosamine derivative Gal-SH of the present invention;
[0032] Figure 3 The synthetic process diagram of the cationic polymer containing photosensitizer in the present invention;
[0033] Figure 4 is a structural analysis diagram of the cationic polymer containing the photosensitizer in the present invention;
[0034] Figure 5 is the particle size distribution diagram of polymer micelle siRNA@GalNPs and siRNA@NPs in Example 6;
[0035] Figure 6 TEM images of polymer micelle siRNA@GalNPs and siRNA@NPs in Example 6;
[0036] Figure 7 This is a graph showing the experimental results of polymer micelle delivery of siRNA in Example 9;
[0037] Figure 8 This is a graph showing the experimental results of polymer micelle delivery of pDNA in Example 10;
[0038] Fig. 9 The graph is a test result of polymer micelles cGAMP+siRNA@GalNPs and cGAMP+siRNA@NPs targeting cancer cells in Example 11;
[0039] Fig.10 This is a graph showing the results of the photodynamic therapy test of polymer micelles cGAMP+siRNA@GalNPs and cGAMP+siRNA@NPs in Example 12. DETAILED DESCRIPTION
[0040] The present invention will be further described below in conjunction with the accompanying drawings and specific embodiments.
[0041] Example 1 Synthesis of amino derivatives of chlorophyllin a PPa-NH2
[0042] Pyrochlorophyllin a (PPa), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI) and N-hydroxysuccinimide (NHS) (molar ratio 1:2:2) were added to a two-necked bottle, and anhydrous dichloromethane and triethylamine (3 mol) were added under an argon atmosphere to fully dissolve the sample. After 4 hours, N-Boc-ethylenediamine hydrochloride (1.2 mol) was added, and the reaction was continued for 24 hours. PPa-NH2Boc was obtained by separation through silica gel column chromatography (methanol: dichloromethane = 2:98). The obtained PPa-NH2Boc was dissolved in dichloromethane, and 4 times the equivalent of trifluoroacetic acid (TFA) was added and stirred for 2 hours. The pH value of the reaction solution was adjusted to neutral with sodium bicarbonate solution, extracted with saturated brine, the organic layer was collected, and concentrated to obtain PPa-NH2. The synthesis process is as shown in the attached Figure 1 shown.
[0043] Example 2 Synthesis of mercaptogalactosamine derivative Gal-SH
[0044] 11-Mercaptoalkanoic acid, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI) and N-hydroxysuccinimide (NHS) (molar ratio 1:2:2) were added to a two-necked bottle. Anhydrous dimethyl sulfoxide was added under an argon atmosphere to fully dissolve the sample. After 6 hours, triethylamine (3 moles) was added, and the reaction solution was observed to become turbid. After stirring for 10 minutes, a solution of 2-amino-2-deoxy-D-galactose hydrochloride (2 moles) dissolved in anhydrous dimethyl sulfoxide was added. After reacting for 24 hours, the reaction solution was added to water and the white precipitate was collected. The white precipitate was dissolved in 1 mol / L sodium hydroxide solution and filtered. The filtrate was adjusted to pH 5 with 1 mol / L hydrochloric acid solution, and a light yellow precipitate was observed to be generated. The precipitate was collected by filtration, washed with pure water, and dried to obtain Gal-SH. The synthesis process is as shown in the attached figure. Figure 2 shown.
[0045] Example 3 Synthesis of photosensitizer-containing cationic polymer
[0046] 1. Synthesis of polymer PPa-PBLA
[0047] The amino derivative PPa-NH2 of pyrochlorophyllin a and L-aspartic acid-4-benzyl ester-N-carboxyl ring anhydride (molar ratio 1:10) were added with anhydrous N,N-dimethylformamide under argon atmosphere to fully dissolve the sample. The reaction was stirred at 37°C for 3 days. After the reaction was completed, the dichloromethane was removed under reduced pressure, and the remaining solvent was placed in a dialysis bag for dialysis and freeze-dried to obtain a block polymer pyrochlorophyllin a-polyaspartic acid (PPa-PBLA) as a gray-green or green powder.
[0048] 2. Synthesis of Polymer PPa-PBLA-PEG-Gal
[0049] The PPa-PBLA obtained in the above step 1 was dissolved in anhydrous N,N-dimethylformamide with maleimide-polyethylene glycol-succinimidyl acetate (PEG) and mercaptogalactosamine derivative (Gal) (molar ratio of the three reactants, 1:1:1), and the reaction was carried out for 24 hours. The reaction solution was precipitated in ether to obtain a block polymer PPa-PBLA-PEG-Gal.
[0050] 3. Formation of PPa-PAsp(DET)-PEG-Gal
[0051] The PPa-PBLA-PEG-Gal obtained in step 2 above was dissolved in NMP, stirred at 10°C until the NMP solution became cold, and then diethylenetriamine (reactant molar ratio, 1:50) was added, and the reaction was stirred for 1 hour. After the reaction was completed, the reaction bottle was placed in an ice-salt bath, and hydrochloric acid solution was slowly added dropwise to neutralize the reaction. Then, it was dialyzed in a dilute HCl solution, and then dialyzed with deionized water, and freeze-dried to obtain PPa-PAsp(DET)-PEG-Gal.
[0052] 4. Obtaining the cationic polymer PPa-PAsp(DET / MPA)-PEG-Gal containing photosensitizer
[0053] Weigh PPa-PAsp(DET)-PEG-Gal (1 mol) obtained in step 3 above and dissolve it in pre-cooled boric acid buffer (pH = 9), add 3,3'-dithiobispropanimidate dimethyl ester dihydrochloride (0.1 mol), and react at room temperature for 1 hour. After the reaction is completed, dialyze with PBS (pH = 7.4) and PBS solution containing 100mM DTT. Finally, dialyze with deionized water for 12 hours and freeze-dry to obtain the cationic polymer PPa-PAsp(DET / MPA)-PEG-Gal containing a photosensitizer. The synthesis process is as shown in the attached Figure 3 As shown, the structural analysis diagram of PPa-PAsp(DET / MPA)-PEG-Gal is shown in the attached Figure 4 shown.
[0054] Example 4 Synthesis of photosensitizer-containing cationic polymer
[0055] 1. Formation of polymer backbone PPa-PBLA
[0056] Weigh the amino derivative PPa-NH2 of pyrochlorophyllin a and L-aspartic acid-4-benzyl ester-N-carboxyl ring anhydride (molar ratio 1:100), add anhydrous dichloromethane under argon atmosphere to fully dissolve the sample. Stir the reaction at 37°C for 3 days. After the reaction is completed, remove dichloromethane under reduced pressure, put the remaining solvent into a dialysis bag for dialysis, and freeze-dry to obtain a block polymer pyrochlorophyllin a-polyaspartic acid (PPa-PBLA) as a gray-green or green powder.
[0057] 2. Formation of block polymer PPa-PBLA-PEG-Gal
[0058] The PPa-PBLA obtained in the above step 1 was dissolved in anhydrous dichloromethane with maleimide-polyethylene glycol-succinimidyl acetate (PEG) and mercaptogalactosamine derivative (Gal) (molar ratio of the three reactants, 1:1:1), and the reaction was carried out for 24 hours. The reaction solution was precipitated in ether to obtain a block polymer PPa-PBLA-PEG-Gal.
[0059] 3. Synthesis of PPa-PAsp(DET)-PEG-Gal
[0060] The PPa-PBLA-PEG-Gal obtained in step 2 above was dissolved in NMP, stirred at 10°C until the NMP solution became cold, and then diethylenetriamine (reactant molar ratio, 1:500) was added, and the reaction was stirred for 3 hours. After the reaction was completed, the reaction bottle was placed in an ice-salt bath, and hydrochloric acid solution was slowly added dropwise to neutralize the reaction. Then, it was dialyzed in a dilute HCl solution, and then dialyzed with deionized water, and freeze-dried to obtain PPa-PAsp(DET)-PEG-Gal.
[0061] 4. Synthesis of cationic polymer PPa-PAsp(DET / MPA)-PEG-Gal containing photosensitizer
[0062] Weigh PPa-PAsp(DET)-PEG-Gal (1 mol) obtained in step 3 above and dissolve it in pre-cooled boric acid buffer (pH = 9), add 3,3'-dithiobispropanimidate dimethyl ester dihydrochloride (0.2 mol), and react at room temperature for 1 hour. After the reaction is completed, dialyze with PBS (pH = 7.4) and PBS solution containing 100mM DTT. Finally, dialyze with deionized water for 12 hours and freeze-dry to obtain the cationic polymer PPa-PAsp(DET / MPA)-PEG-Gal containing a photosensitizer. The synthesis process is as shown in the attached Figure 3 As shown, the structural analysis diagram of PPa-PAsp(DET / MPA)-PEG-Gal is shown in the attached Figure 4 shown.
[0063] Example 5 Synthesis of Cationic Polymer Containing Photosensitizer
[0064] 1. Formation of polymer backbone PPa-PBLA
[0065] Weigh the amino derivative PPa-NH2 of pyrochlorophyllin a and L-aspartic acid-4-benzyl ester-N-carboxyl ring anhydride (molar ratio 1:150), add anhydrous dichloromethane under argon atmosphere to fully dissolve the sample. Stir the reaction at 37°C for 3 days. After the reaction is completed, remove dichloromethane under reduced pressure, put the remaining solvent into a dialysis bag for dialysis, and freeze-dry to obtain a block polymer pyrochlorophyllin a-polyaspartic acid (PPa-PBLA) as a gray-green or green powder.
[0066] 2. Formation of block polymer PPa-PBLA-PEG-Gal
[0067] The PPa-PBLA obtained in the above step 1 was dissolved in anhydrous N,N-dimethylformamide with maleimide-polyethylene glycol-succinimidyl acetate (PEG) and mercaptogalactosamine derivative (Gal) (molar ratio of the three reactants, 1:1.5:1.5), and the reaction was carried out for 24 hours. The reaction solution was precipitated in ether to obtain a block polymer PPa-PBLA-PEG-Gal.
[0068] 3. Formation of PPa-PAsp(DET)-PEG-Gal
[0069] The PPa-PBLA-PEG-Gal obtained in step 2 above was dissolved in NMP, stirred at 10°C until the NMP solution became cold, and then diethylenetriamine (reactant molar ratio, 1:500) was added, and the reaction was stirred for 5 hours. After the reaction was completed, the reaction bottle was placed in an ice-salt bath, and hydrochloric acid solution was slowly added dropwise to neutralize the reaction. Then, it was dialyzed in a dilute HCl solution, and then dialyzed with deionized water, and freeze-dried to obtain PPa-PAsp(DET)-PEG-Gal.
[0070] 4. Obtaining the cationic polymer PPa-PAsp(DET / MPA)-PEG-Gal containing photosensitizer
[0071] Weigh PPa-PAsp(DET)-PEG-Gal (1 mol) obtained in step 3 above and dissolve it in pre-cooled boric acid buffer (pH = 9), add 3,3'-dithiobispropanimidate dimethyl ester dihydrochloride (0.5 mol), and react at room temperature for 1 hour. After the reaction is completed, dialyze with PBS (pH = 7.4) and PBS solution containing 100mM DTT. Finally, dialyze with deionized water for 12 hours and freeze-dry to obtain the cationic polymer PPa-PAsp(DET / MPA)-PEG-Gal containing a photosensitizer. The synthesis process is as shown in the attached figure. Figure 3 As shown, the structural analysis diagram of PPa-PAsp(DET / MPA)-PEG-Gal is shown in the attached Figure 4 shown.
[0072] Example 6 Preparation of siRNA-loaded polymer micelles
[0073] The photosensitizer-containing cationic polymer PPa-PAsp(DET / MPA)-PEG-Gal (prepared in Example 4) was dissolved in HEPES buffer (10mM, pH=7.4) to prepare a 10μg / μL PPa-PAsp(DET / MPA)-PEG-Gal solution. PD-L1 siRNA ((self-sequence, commissioned by Shanghai Bioengineering, 1μg / μL) was dissolved in HEPES buffer (10mM, pH=7.4) to prepare a 1μg / μL siRNA solution. 60μL of PD-L1 siRNA solution was added to 30μL of PPa-PAsp(DET / MPA)-PEG-Gal solution, and the mixture was mixed to obtain polymer micelle siRNA@GalNPs.
[0074] The PD-L1 siRNA sequences are shown in SEQ ID No. 1 and SEQ ID No. 2 (SEQ ID No. 1: GGCGUUUACUGCUGCAUAATT, SEQ ID No. 2: UUAUGCAGCAGUAAACGCCTT).
[0075] According to the above method, cationic polymers without target molecules were used to obtain polymer micelles siRNA@NPs without target molecules. The particle sizes of the obtained polymer micelles siRNA@GalNPs and siRNA@NPs were between 10–200 nm, such as Figure 5 The obtained two polymer micelles were observed by transmission electron microscopy to have uniform particle size distribution, as shown in Figure 6 shown.
[0076] Example 7 Preparation of polymer micelles loaded with siRNA and cyclic guanosine monophosphate (2',3'-cGAMP)
[0077] The cationic polymer PPa-PAsp(DET / MPA)-PEG-Gal containing a photosensitizer (prepared in Example 4) was dissolved in HEPES buffer (10mM, pH=7.4) to prepare a 10μg / μL PPa-PAsp(DET / MPA)-PEG-Gal solution. PD-L1 siRNA (self-sequence, commissioned by Shanghai Shenggong for synthesis, 1μg / μL) and 2'3'-cGAMP (1μg / μL, purchased from Haihuakang Biotechnology Co., Ltd.) were dissolved in HEPES buffer (10mM, pH=7.4). 60μL of PD-L1 siRNA and 2'3'-cGAMP solution were added to 60μL of PPa-PAsp(DET / MPA)-PEG-Gal solution and mixed to obtain polymer micelles cGAMP+siRNA@GalNPs.
[0078] According to the above method, cationic polymers without target molecules were used to obtain polymer micelles cGAMP+siRNA@NPs without target molecules. The particle sizes of the obtained polymer micelles cGAMP+siRNA@GalNPs and cGAMP+siRNA@NPs were both between 10–200 nm. The particle size distribution of the above two polymer micelles was uniform when observed by transmission electron microscopy.
[0079] Example 8 Preparation of polymer micelles (containing pDNA and cationic polymer containing photosensitizer)
[0080] The cationic polymer PPa-PAsp(DET / MPA)-PEG-Gal containing a photosensitizer (prepared in Example 4) was dissolved in HEPS buffer (10mM, pH=7.4) to prepare a 10μg / μL PPa-PAsp(DET / MPA)-PEG-Gal solution. The pDNA expressing enhanced green fluorescent protein (the nucleotide sequence of pDNA is shown in SEQ ID No.3) was dissolved in HEPS buffer (10mM, pH=7.4) to prepare a 1μg / μL pDNA solution. 60μL of pDNA solution was added to 30μL of PPa-PAsp(DET / MPA)-PEG-Gal solution, and the mixture was mixed to obtain polymer micelles pDNA@GalNPs.
[0081] Example 9 Experiment of polymer micelle delivery of siRNA to cells
[0082] The polymer micelle siRNA@GalNPs and polymer micelle siRNA@NPs prepared in Example 6 were prepared in a cell culture medium to make the final concentration of PD-L1 siRNA 2 μg / mL. The cell culture medium containing siRNA polymer micelles was acted on B16F10 cells, and the cells were collected after 24 hours of culture, and the expression of PD-L1 protein was analyzed by Western blot. Figure 7 As shown, compared with the blank group and the siRNA group, the nanoparticle groups siRNA@GalNPs and siRNA@NPs significantly reduced the expression of PD-L1 protein, indicating that the photosensitizer-containing cationic polymer in the present invention has the function of efficiently delivering siRNA.
[0083] Example 10: Experimental verification of the effect of polymer micelle delivery of pDNA
[0084] The pDNA polymer micelles pDNA@GalNPs prepared in Example 8 were prepared in a cell culture medium to make the final pDNA concentration 10 μg / mL. The cell culture medium containing the polymer micelles pDNA@GalNPs was applied to 293T cells (from the cell bank of the Chinese Academy of Sciences, cryopreserved by the State Key Laboratory of Biotherapy). After culturing for 24 hours, the fluorescence of enhanced green fluorescent protein was observed using a fluorescence microscope. Figure 8 As shown, enhanced green fluorescent protein is more expressed, indicating that the cationic polymer containing photosensitizer in the present invention has the ability to efficiently deliver pDNA.
[0085] Example 11 Experiment on polymer micelle delivery of siRNA and cGAMP targeting cancer cells
[0086] The two polymer micelles loaded with siRNA and cGAMP (cGAMP+siRNA@GalNPs and cGAMP+siRNA@NPs) prepared in Example 7 were prepared in a cell culture medium to make the final concentration of PD-L1 siRNA 2 μg / mL. The cell culture medium of the above two polymer micelles was acted on B16F10 cells (from the cell bank of the Chinese Academy of Sciences, cryopreserved by the State Key Laboratory of Biotherapy), and after 6 hours of culture, the culture medium was replaced with fresh culture medium, and the cells were irradiated with a 660nm laser (100mW / cm 2 , 5min) and then cultured for 4h. The cells were stained with LysoTracker Green DND-26 for lysosomes and Hoecst33342 for nuclei. Laser confocal microscopy was used to observe the co-localization of polymer micelles and lysosomes. Fig. 9 As shown, both polymer micelles can destroy lysosomes, indicating that siRNA, cGAMP and photosensitizer are delivered to B16F10 cells at the same time; and the fluorescence of cGAMP+siRNA@GalNPs is stronger than that of the cGAMP+siRNA@NPs group, indicating that B16F10 cells take up more cGAMP+siRNA@GalNPs, which is because the galactose modified by cGAMP+siRNA@GalNPs polymer micelles has the effect of targeting cancer cells.
[0087] Example 12 Polymer micelles for photodynamic therapy and immunotherapy of tumors
[0088] The two polymer micelles (cGAMP+siRNA@GalNPs and cGAMP+siRNA@NPs) prepared in Example 7 were injected into the tumor site, respectively. 6 h after drug injection, the tumor site was irradiated with laser (660 nm, 200 mW / cm 2,5min) to achieve photodynamic therapy of tumors. The control group was injected with polymer micelles only without light exposure. The tumor volume was measured every other day. Fig.10 As shown, compared with the cGAMP+siRNA@GalNPs group and cGAMP+siRNA@NPs group without light irradiation, the cGAMP+siRNA@GalNPs+light irradiation group and the cGAMP+siRNA@NPs+light irradiation group can significantly inhibit the size of the tumor, indicating that the polymer micelles cGAMP+siRNA@GalNPs and cGAMP+siRNA@NPs have significant photodynamic therapy and immunotherapy effects.
[0089] In summary, the cationic polymer containing photosensitizer in the present invention, and gene drugs (siRNA, pDNA) or negatively charged small molecule drugs (cyclic guanosine monophosphate) are combined through positive and negative charges to form polymer micelles, which effectively improve the transfection ability of the cationic polymer and the drug delivery efficiency (Examples 9-10); and the polymer micelles can simultaneously deliver photosensitizers and drugs directly to target cells (Examples 11-12), and also have a significant photodynamic therapy effect on tumors (Example 12).
[0090] The specification and drawings of the present invention are considered to be illustrative rather than restrictive. On the basis of the present invention, those skilled in the art can make some substitutions and modifications to some of the technical features according to the disclosed technical content without creative labor, all of which are within the protection scope of the present invention.
Claims
1. A polymer, characterized in that The polymer is galactose-polyethylene glycol-poly{N-[N'-(2-aminoethyl) / (1-(3-mercaptopropyl)amino))-2-aminoethyl]aspartic acid}-pyrodeoxychlorophyllin a block polymer PPa-PAsp(DET / MPA)-PEG-Gal; the structural formula of the polymer is shown in formula (I): Formula (I) Among them, x is 1-100; n is 1-100; m is 1-100.
2. The method for preparing a polymer according to claim 1, characterized in that: The following steps are involved: S1, PPa-NH2 and L-aspartic acid-4-benzyl ester-N-carboxyl cyclic anhydride (BLA-NCA) are polymerized at a molar ratio of 1:10-150 to form a polymer skeleton pyropheophorbide a-polyaspartate PPa-PBLA; the PPa-NH2 is an amino derivative of pyropheophorbide a (Pyropheophorbide a, PPa); S2, reacting the polymer backbone PPa-PBLA in S1 with maleimide-polyethylene glycol-succinimidyl acetate and 11-mercaptogalactosamine derivative at a molar ratio of 1:1:1 to form a block polymer PPa-PBLA-PEG-Gal; S3, reacting the block polymer PPa-PBLA-PEG-Gal in S2 with diethylenetriamine at a molar ratio of 1:10-500 to form PPa-PAsp(DET)-PEG-Gal; S4. The PPa-PAsp(DET)-PEG-Gal in S3 is reacted with 3,3'-dithiobispropanimidic acid dimethyl ester dihydrochloride at a molar ratio of 1:10-300, and a thiol group is introduced into the side chain of 3,3'-dithiobispropanimidic acid dimethyl ester dihydrochloride to obtain a polymer PPa-PAsp(DET / MPA)-PEG-Gal, which is a cationic polymer.
3. A polymer micelle, characterized in that Comprising a drug and the polymer according to claim 1.
4. A polymer micelle according to claim 3, characterized in that: The drug is one or both of a gene drug and a negatively charged small molecule drug.
5. A polymer micelle according to claim 4, characterized in that: The gene medicine is RNA or DNA.
6. A polymer micelle according to claim 4, characterized in that: The negatively charged small molecule drug is cyclic guanosine monophosphate adenosine.
7. A polymer micelle according to claim 3, characterized in that: The particle size of the polymer micelle is 10-200 nm.
8. The method for preparing polymer micelles according to any one of claims 3 to 7, characterized in that: The polymer and the drug are dissolved in HEPS buffer or an organic solvent respectively, mixed and self-assembled to obtain the polymer micelle loaded with the drug; the organic solvent is tetrahydrofuran.
9. Use of the polymer micelle according to any one of claims 3 to 7 in the preparation of drugs for gene therapy, immunotherapy, phototherapy and chemotherapy.
